Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | Q9HBH1 | 10/20 | 0.71 | |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801241 | 0.87 | PDF (0.73) | PDFMAPTKDM4EMAPK1RAB9A | |
| SCHEMBL13077062 | 0.86 | PDF (0.71) | PDFMAPTKDM4EMAPK1RAB9A | |
| SCHEMBL290648 | 0.83 | PDF (1.00) | PDFMAPTKDM4EMAPK1RAB9A | |
| SCHEMBL290315 | 0.81 | PDF (1.00) | PDFMAPTKDM4EMAPK1RAB9A | |
| SCHEMBL801722 | 0.80 | PDF (0.63) | PDFMAPTKDM4EMAPK1RAB9A | |
| SCHEMBL288858 | 0.79 | PDF (1.00) | PDFMAPTKDM4EMAPK1RAB9A | |
| SCHEMBL299173 | 0.78 | PDF (0.69) | PDFMAPTKDM4EMAPK1RAB9A | |
| SCHEMBL801284 | 0.77 | PDF (0.66) | PDFMAPT | |
| SCHEMBL801885 | 0.76 | PDF (0.71) | PDFMAPTKDM4EMAPK1RAB9A | |
| SCHEMBL16994921 | 0.74 | PDF (0.67) | PDFMAPTKDM4EMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2959898-A1 | 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2010129049-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | PDF, EIF5B, EIF4E | PDF 1/4885MAPT 3128/4885KDM4E 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.